Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer

Table 1 Toxicities of oxaliplatin plus capecitabine in 64 cases of metastatic ESCC (n %)

Side effects	Grade
	0	I	II	III	IV
Nausea and vomiting	31 (48.4)	21 (32.8)	12 (18.8)	0 (0.0)	0 (0.0)
Diarrhea	32 (50.0)	20 (31.3)	12 (18.7)	0 (0.0)	0 (0.0)
Aspherinia	44 (68.7)	11 (17.2)	9 (14.1)	0 (0.0)	0 (0.0)
Leukopoenia	32 (50.0)	20 (31.3)	10 (15.6)	2 (3.1)	0 (0.0)
Thrombocytopenia	46 (71.9)	11 (17.2)	7 (10.9)	0 (0.0)	0 (0.0)
Nerve toxicity	40 (62.5)	14 (21.9)	9 (14.1)	1 (1.5)	0 (0.0)
Hand-foot syndrome	40 (62.5)	13 (20.3)	11 (17.2)	0 (0.0)	0 (0.0)
Alopecia	60 (93.8)	4 (6.2)	0 (0.0)	0 (0.0)	0 (0.0)
Mucositis of mouth	39 (60.9)	18 (28.1)	7 (10.9)	0 (0.0)	0 (0.0)
Abnormal liver function	56 (87.6)	7 (10.9)	1 (1.5)	0 (0.0)	0 (0.0)

Table 2 Prognostic single factor analysis of ESCC

Prognostic factor	Number	Survival rate (%)		MST (mo)	P
		1-yr	2-yr
Sex					0.713
Male	42	38.1	7.1	10.0
Female	119	26.3	10.5	8.5
Age (Yr)					0.887
< 60	26	30.8	11.5	9.0
≥ 60	35	42.9	5.7	10.0
KPS					< 0.001
60-80	40	22.5	0.0	8.0
90-100	21	66.7	23.8	13.5
Metastasis					< 0.001
Mono-site	40	52.5	12.5	12.5
Poly-site	21	9.5	0.0	6.5
Prechemotherapy					0.969
Yes	27	40.7	3.7	10.0
No	34	35.3	11.8	9.0
Therapeutic effect
PR	27	63.0	18.5	13.0
SD	24	25.0	0.0	9.0
PD	10	0.0	0.0	6.0

Table 3 Results of proportional hazards regression model

Factor	Regression coefficient	Standard error	Wald	DOF	P	Exp (β)	95% CI
Sex	-0.439	0.361	1.475	1	0.225	0.645	0.318-1.309
Age	-0.151	0.342	0.194	1	0.659	0.860	0.440-1.682
KPS	-1.449	0.342	17.906	1	< 0.001	0.235	0.120-0.459
Metastasis	1.932	0.390	24.497	1	< 0.001	6.902	3.212-14.833
Pre-chemotherapy	-0.235	0.291	0.653	1	0.419	0.790	0.447-1.398
Short-term effect	0.972	0.254	14.610	1	< 0.001	2.645	1.606-4.354